
Opinion|Videos|January 20, 2025
Future Perspectives on the Relapsed/Refractory Follicular Lymphoma Treatment Landscape
Author(s)Juan Pablo Alderuccio, MD
A panelist discusses how, despite recent advances in relapsed/refractory follicular lymphoma treatment, important unmet needs are being addressed through ongoing trials while reflecting on proud accomplishments in the field and expressing enthusiasm for developments in the coming year.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What are some remaining unmet needs in treating relapsed/refractory follicular lymphoma?
- What trials of interest are ongoing? What are future considerations?
- What accomplishments in this space are you most proud of?
- What are you most excited about in the coming year?
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Improving Survival, Quality of Life, and Cost-Effectiveness for Allo-HCT
2
FDA Approves SimpleScreen Blood Test for CRC Screening
3
Behind the Gedatolisib FDA Approval: An Investigator's Perspective on HR+ Breast Cancer
4
Emavusertib/Ibrutinib Combo Shows Deepening Responses in PCNSL
5
























